Invivyd outlines VYD2311 path as PEMGARDA grows 22% year-over-year while DECLARATION recruitment nears completion

Q1 2026 Management View "We triggered our DECLARATION study upsizing in early April, and the recruitment speed into this additional upsized cohort occurred well faster than our internal expectations" ...
MarketBeat on MSN

Invivyd Q1 earnings call highlights

Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody ...
newscase

BioNTech’s €532 Million Loss Accelerates Restructuring and a New Executive Compensation Playbook

The pandemic-era bonanza is firmly in the rearview mirror at BioNTech, replaced by a searing quarterly loss and a sweeping ...
The Manila Times

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued ...

CDC to Weigh Adding Covid-19 Vaccine Injury Medical Codes

The Centers for Disease Control and Prevention is gathering feedback on a proposal that would create a medical code to track ...

How The U.S. Is Making The Same Mistakes With Hantavirus As It Did With COVID-19

A public health expert explains why the United States is repeating the same mistake with the Hantavirus response as with ...